ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: TH-OR120

Polygenic Risk Score as a Determinant of Risk of Non-Melanoma Skin Cancer Post-Renal Transplantation

Session Information

Category: Transplantation

  • 1701 Transplantation: Basic and Experimental


  • Stapleton, Caragh P., Royal College of Surgeons, Dublin, Ireland
  • Birdwell, Kelly A., Vanderbilt University, Nashville, Tennessee, United States
  • Mark, Patrick B., University of Glasgow, Glasgow, United Kingdom
  • Sanders, M. Lee, University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
  • Phelan, Paul J., Royal Infirmary of Edinburgh, NHS Lothian, Edinburgh, United Kingdom
  • Maxwell, Alexander P., Queen's University Belfast, Belfast, United Kingdom
  • McKnight, A.J., Queen's University Belfast, Belfast, United Kingdom
  • Kennedy, Claire, Beaumont Hospital, Dublin 9, Dublin, Ireland
  • Jardine, Alan G., University of Glasgow, Glasgow, United Kingdom
  • Traynor, Jamie P., NHS Greater Glasgow and Clyde, Glasgow, United Kingdom
  • Chapman, Fiona A, NHS Scotland, Glasgow, United Kingdom
  • Keating, Brendan, University of Pennsylvania, Philadelphia, Pennsylvania, United States
  • Conlon, Peter J., Beaumont Hospital, Dublin 9, Dublin, Ireland
  • Cavalleri, Gianpiero, Royal College of Surgeons, Dublin, Ireland

Group or Team Name

  • International Genetics & Translational Research in Transplantation Network

Multiple genetic loci have been identified for non-melanoma skin cancer (NMSC) in the general population. Polygenic risk score (PRS) was defined as the sum of all alleles associated with a trait weighted by the effect size of that allele as determined by a previous genome-wide association study (GWAS). We tested whether PRS, calculated using a GWAS of NMSC in a non-transplant population, can be used to determine risk of developing and time to NMSC post-kidney transplant.


Post-kidney transplant NMSC cases (n=155) and controls (n=442) were collected from Tennessee, Ireland and Scotland. Genetic variants that reached pre-defined levels of significance were chosen from a squamous cell carcinoma (SCC), and a basal cell carcinoma (BCC) GWAS, both conducted in non-transplant populations. Using these GWAS results, BCC and SCC PRSs were calculated at each p-value threshold (pT) for each sample in the renal transplant cohorts. PRSs were normalized so mean = 0 and standard deviation = 1. PRSs were tested as a predictor of case: control status in a logistic regression model and time to NMSC post-transplant in a survival model. Age of recipient at transplant, recruitment centre, azathioprine exposure and the first four principal components were included as covariates in both models.


SCC PRS calculated at pT of 1x10-6 was the most significant predictor of case: control status of NMSC post-transplant (OR per 1 standard deviation increase in PRS = 2.3; corrected P (Pc) =0.04). When we subdivided NMSC into SCC and BCC, SCC PRS pT 1x10-6 was a significant predictor of case:control SCC (OR = 2.5, Pc = 0.02) and BCC status (OR = 7.6, Pc = 0.02). SCC PRS pT 1x10-5 was also a significant predictor of time to post-transplant BCC (Pc = 0.007, HR = 1.8) and SCC (Pc = 0.05, HR = 1.4).


PRS of non-transplant NMSC can be used to predict case:control status of post-transplant NMSC, SCC and BCC as well as time to developing BCC and SCC post-transplant.


  • Government Support - Non-U.S.